as 07-26-2024 4:00pm EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | ALACHUA |
Market Cap: | 290.2M | IPO Year: | N/A |
Target Price: | $13.00 | AVG Volume (30 days): | 336.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.50 | EPS Growth: | N/A |
52 Week Low/High: | $3.45 - $10.83 | Next Earning Date: | 08-05-2024 |
Revenue: | $163,726,000 | Revenue Growth: | 13.51% |
Revenue Growth (this year): | 14.73% | Revenue Growth (next year): | 12.98% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 33,028 | $253,655.04 | 1,124,565 | SEC Form 4 |
Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 3,086 | $23,700.48 | 1,133,979 | SEC Form 4 |
Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 3,166 | $24,314.88 | 1,143,788 | SEC Form 4 |
DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 716 | $5,498.88 | 165,661 | SEC Form 4 |
DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 721 | $5,537.28 | 167,890 | SEC Form 4 |
DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 3,141 | $24,122.88 | 177,474 | SEC Form 4 |
Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 5,251 | $40,327.68 | 52,999 | SEC Form 4 |
Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 1,020 | $7,833.60 | 56,104 | SEC Form 4 |
Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 610 | $4,684.80 | 57,994 | SEC Form 4 |
Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 716 | $5,498.88 | 37,992 | SEC Form 4 |
Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 721 | $5,537.28 | 40,221 | SEC Form 4 |
Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 4,596 | $35,297.28 | 54,250 | SEC Form 4 |
Donovan Michael Patrick | AXGN | VP Operations | Mar 7 '24 | Sell | $8.81 | 36,310 | $319,891.10 | 35,708 | SEC Form 4 |
Freitag Gregory Gene | AXGN | Director | Mar 7 '24 | Sell | $9.00 | 25,000 | $225,000.00 | 271,594 | SEC Form 4 |
MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.52 | 1,410 | $10,603.20 | 74,693 | SEC Form 4 |
MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.51 | 3,120 | $23,431.20 | 71,573 | SEC Form 4 |
MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.50 | 7,970 | $59,775.00 | 63,603 | SEC Form 4 |
AXGN Breaking Stock News: Dive into AXGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Zacks
14 days ago
GlobeNewswire
a month ago
MT Newswires
a month ago
Zacks
a month ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
Zacks
a month ago
The information presented on this page, "AXGN Axogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.